PULSE.D-01 / CARDIO UNIT
REV 2.6 / BUILD 41A
—
●UPLINK STABLE
PULSE®
REQ. DISPATCH
DEVICE // PULSE-D01REV 2.6COORDS 40.7128°N / 74.0060°WSTATUS /// ARMEDUPLINK OKLATENCY 24MSCHANNEL-07CPU 41%PAYLOAD VERIFIEDSYNC 1:1SIGNAL -38DBTHERMAL 37.0°CDEVICE // PULSE-D01REV 2.6COORDS 40.7128°N / 74.0060°WSTATUS /// ARMEDUPLINK OKLATENCY 24MSCHANNEL-07CPU 41%PAYLOAD VERIFIEDSYNC 1:1SIGNAL -38DBTHERMAL 37.0°CDEVICE // PULSE-D01REV 2.6COORDS 40.7128°N / 74.0060°WSTATUS /// ARMEDUPLINK OKLATENCY 24MSCHANNEL-07CPU 41%PAYLOAD VERIFIEDSYNC 1:1SIGNAL -38DBTHERMAL 37.0°C
MANIFEST // CARDIOVASCULAR INTEL
UNIT
PULSE-D-01
OPERATOR
CLASS-A / LICENSED
CHANNELS
12-LEAD / STRAIN / CMR
DUTY CYCLE
24 / 7 / 365
GEO
40.7128°N / 74.0060°W
STATUS
■ ARMED
[ BRIEF ]

> A cardiology unit engineered like a flight deck. Twelve diagnostic channels, zero-referral imaging, genomic risk panels and a monitoring team that watches your rhythm while you sleep. Prevention, surveillance, reversal. No soft language.

[ DISPLAY / HERO-A ]

CARDIO
//INTEL

HR.LIVE
0
BPM
SPO₂
0
%
APOB
0
MG/DL
[ CHANNEL-07 / LEAD-II ]
STREAM 500Hz● REC
UID // PT-8843-9F1E
[ SECTION 01 ]

LIVE
VITALS

> EIGHT CHANNELS. CONTINUOUSLY MONITORED. THRESHOLDS SET BY YOUR PHYSICIAN, NOT A TEMPLATE.

CH-01● NOMINAL
62
BPM
HEART RATE58–72
CH-02● NOMINAL
118/76
MMHG
SYS / DIA110/70–120/80
CH-03● NOMINAL
98
%
SPO₂95–100
CH-04● NOMINAL
14
BRPM
RESP RATE12–18
CH-05● NOMINAL
36.8
°C
CORE TEMP36.1–37.2
CH-06● NOMINAL
84
MG/DL
LDL-C< 100
CH-07● MONITOR
72
MG/DL
APOB< 80
CH-08● NOMINAL
0.9
MG/L
HS-CRP< 2.0
[ SECTION 02 / PROTOCOL STACK ]

THE
PROTOCOL

> SIX DIAGNOSTIC RUNS. RUN ONCE, RUN SERIALLY, RUN COMBINED. EACH ONE RETURNS A STRUCTURED, VERSION-CONTROLLED REPORT.
[P-001]
01 / 6
LABWINDOWT+00:00 / T+00:72

ADVANCED LIPID PANEL

> Apolipoprotein B, Lp(a), full lipoprotein particle analysis. Biomarkers against atherosclerotic cardiovascular disease risk.

PRECISION99.7%///VIEW SPEC →
[P-002]
02 / 6
IMAGINGWINDOWT+00:00 / T+00:25

CORONARY CT ANGIOGRAPHY

> 256-slice multidetector row. Non-invasive visualization of coronary artery stenosis and plaque burden quantification.

PRECISION98.2%///VIEW SPEC →
[P-003]
03 / 6
MONITORWINDOWT+00:00 / T+336:00

CONTINUOUS HOLTER

> 14-day wearable ECG. Captures arrhythmia, ectopy, atrial fibrillation across continuous ambulatory signal.

PRECISION96.1%///VIEW SPEC →
[P-004]
04 / 6
IMAGINGWINDOWT+00:00 / T+00:40

ECHOCARDIOGRAPHIC STRAIN

> Global longitudinal strain mapping. Subclinical dysfunction detection beyond conventional ejection fraction.

PRECISION97.4%///VIEW SPEC →
[P-005]
05 / 6
STRESSWINDOWT+00:00 / T+00:60

CPET / GAS-EXCHANGE

> Cardiopulmonary exercise test. VO2max, anaerobic threshold, oxygen-pulse — the definitive physiologic load test.

PRECISION95.9%///VIEW SPEC →
[P-006]
06 / 6
GENOMICSWINDOWT+00:00 / T+72:00

GENETIC RISK PANEL

> Polygenic risk score across 140 cardiovascular loci. Heritable lipid disorders, cardiomyopathy, thrombophilia.

PRECISION99.9%///VIEW SPEC →
[ SECTION 03 / AGGREGATE TELEMETRY ]
ENROLLED SUBJECTS
0
PT
EVENTS AVERTED / 24MO
0
CV
AVG APOB REDUCTION
0
%
MEMBER RETENTION
0
%
[ SECTION 04 / OPERATORS ]

THE CREW

> BOARD-CERTIFIED. FELLOWSHIP-TRAINED. FOUR DISCIPLINES UNDER ONE ROOF. CASES ARE REVIEWED IN DAILY STAND-UP AT 07:30 LOCAL.

SPEC-0117 YR / IN FIELD

DR. E. VARGAS

MD / FACC / PHD
INTERVENTIONAL
VERIFY ▸ NPISECURE / TLS-1.3
SPEC-0212 YR / IN FIELD

DR. N. OKAFOR

MD / FHRS
ELECTROPHYSIOLOGY
VERIFY ▸ NPISECURE / TLS-1.3
SPEC-0310 YR / IN FIELD

DR. S. LIU

MD / MPH
PREVENTIVE
VERIFY ▸ NPISECURE / TLS-1.3
SPEC-0414 YR / IN FIELD

DR. A. NOVAK

MD / PHD
IMAGING
VERIFY ▸ NPISECURE / TLS-1.3
[ SECTION 05 / CASEFILE ]

DOSSIER // PT

> ANONYMIZED, CONSENTED, AUDIT-TRAILED. OUTCOMES AT 12–24 MONTHS ON STANDARD PROTOCOL COMBINATIONS.
FILE // CF-0417● ACTIVE
[ SUBJECT ]
SUBJ-K. // MALE / 54
PRESET / SILENT CAD

> Calcium score 412 on routine scan. Zero symptoms. Entered protocol P-002 / P-001. Reverse-remodeling plan initiated.

Δ OUTCOME−38% LDL-C at 180 DAY
FILE // CF-0502● ACTIVE
[ SUBJECT ]
SUBJ-L. // FEMALE / 41
PRESET / PALPITATIONS

> 14-day Holter identified paroxysmal AF, 3 episodes nocturnal. Rhythm-control strategy elected. Catheter ablation T+90.

Δ OUTCOME0 RECURRENCE / 12 MO
FILE // CF-0611● ACTIVE
[ SUBJECT ]
SUBJ-M. // MALE / 67
PRESET / HEART FAILURE

> HFpEF with strain-detected dysfunction. Quad therapy titrated. 6MWT +82m. KCCQ +24. Off supplemental diuretic.

Δ OUTCOMEEF +6PP / 24 WEEK
[ SECTION 06 / FAQ ]

QUERY
LOG

> MOST-ASKED. MAINTAINED BY THE CLINICAL OPERATIONS LEAD.

  • > Intake runs continuously. First diagnostic pass is scheduled within 72 hours of enrollment. Full cardiovascular risk brief is issued at T+14 days.
[ DISPATCH TERMINAL ]

REQUEST
INTAKE

> FILE A DISPATCH. A MEDICAL OPERATIONS LEAD WILL CONTACT YOU WITHIN 48 HOURS TO SCHEDULE INTAKE, CONFIRM INSURANCE AND ISSUE YOUR FIRST PROTOCOL ORDERS.

> END-TO-END ENCRYPTED · HIPAA-AUDITED · REV 2.6